Myocardial damage during percutaneous interventions for non-ST-elevation acute coronary syndromes

European Heart Journal, Supplement

Volumn 7, Issue K, 2005, Pages

  Bolognese, Leonardo ^a   Falsini, Giovanni ^a   Liistro, Francesco ^a   Angioli, Paolo ^a  

^a Azienda Ospedaliera Arezzo   (Italy)

Author keywords

Acute coronary syndromes; GP IIb IIIa inhibitors; Myocardial damage

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CREATINE KINASE MB; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; SIBRAFIBAN; TIROFIBAN; TROPONIN; TROPONIN I;

BLOOD CLOT LYSIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTRAST ECHOCARDIOGRAPHY; ENZYME RELEASE; HEALTH CARE COST; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HUMAN; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS;

EID: 26644446709     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sui069     Document Type: Conference Paper

References (26)

1. Landau C, Lange RA, Hillis LD. Percutaneous transluminal coronary angioplasty. N Engl J Med 1994;330:981-993.
2. Mukherjee D, Oz M, Prager R et al. Elective coronary revascularization, an iatrogenic form of acute coronary syndrome: how can clinicians reduce the risks? Am Heart J 2004;148:371-377.
3. Cavallini C, Savonitto S, Violini R et al. Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. Eur Heart J, 2005;26:1494-1498.
4. Morrow DA, Cannon CP, Rifai N et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST-elevation myocardial infarction: results from a randomized trial. JAMA 2001;286:2405-2412.
5. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 2000;101:570-580.
6. Waxman S, Sassower MA, Mittleman MA et al. Angioscopic predictors of early adverse outcome after coronary angioplasty in patients with unstable angina and non-Q-wave myocardial infarction. Circulation 1996;93:2106-2113.
7. Okamatsu K, Takano M, Sakai S et al. Elevated troponin T levels and lesion characteristics in non-ST-elevation acute coronary syndromes. Circulation 2004;109:465-470.
8. Fuchs S, Gruberg L, Singh S et al. Prognostic value of cardiac troponin I re-elevation following percutaneous coronary intervention in high-risk patients with acute coronary syndromes. Am J Cardiol 2001; 88:129-133.
9. Cantor WJ, Newby LK, Christenson RH et al. Prognostic significance of elevated troponin I after percutaneous coronary intervention. J Am Coll Cardiol 2002;39:1738-1744.
10. Nageh T, Sherwood RA, Harris BM et al. Cardiac troponin I for risk stratification following percutaneous coronary artery intervention in acute coronary syndromes. Catheter Cardiovasc Interv 2002;55:37-42.
11. Roe MT, Mahaffey KW, Kilaru R et al. Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes. Eur Heart J 2004;25:313-321.
12. Nallamothu BK, Bates ER. Periprocedural myocardial infarction and mortality: causality versus association. J Am Coll Cardiol 2003;42:1412-1414.
13. Kanaparti PK, Brown DL. Relation between coronary atherosclerotic plaque burden and cardiac enzyme elevation following percutaneous coronary intervention. Am J Cardiol 2000;86:619-622.
14. Mehran R, Dangas G, Mintz GS et al. Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions: intravascular ultrasound study of 2256 patients. Circulation 2000;101:604-610.
15. Topol EJ. A guide to therapeutic decision-making in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 2003;41:123S-129S.
16. Heeschen C, van Den Brand MJ, Hamm CW et al. Angiographic findings in patients with refractory unstable angina according to troponin T status. Circulation 1999;100:1509-1514.
17. Gibson CM, Murphy SA, Marble SJ et al. Relationship of creatine kinase-myocardial band release to thrombolysis in myocardial infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy. Am Heart J 2002;143:106-110.
18. Wong GC, Morrow DA, Murphy S et al. Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Circulation 2002;106:202-207.
19. Bolognese L, Ducci K, Angioli P et al. Elevations in troponin I after percutaneous coronary interventions are associated with abnormal tissue-level perfusion in high-risk patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2004;110:1592-1597.
20. Stadius ML. Diminishing returns and too many choices: the saga of pharmacologic therapy to reduce the complications of percutaneous coronary intervention. J Am Coll Cardiol 2004;44:25-27.
21. Soffer D, Moussa I, Karatepe M et al. Suboptimal inhibition of platelet aggregation following tirofiban bolus in patients undergoing percutaneous coronary intervention for unstable angina pectoris. Am J Cardiol 2003;91:872-875.
22. Kabbani SS, Aggarwal A, Terrien EF et al. Sub-optimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol 2002;89:647-650.
23. Schneider DJ, Herrmann HC, Lakkis N et al. Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. Am J Cardiol 2003;91:163-166.
24. Antman EM. Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST-segment elevation myocardial infarction: appropriate interpretation of the guidelines. Am Heart J 2003;146:S18-S22.
25. Cannon CP, Weintraub WS, Demopoulos LA et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-1887.
26. Bolognese L, Falsini G, Liistro F et al. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial. J Am Coll Cardiol, in press.